Orchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial Operations
Commercial team preparing for potential gene therapy launches
Boston, Mass., USA and London, UK, November 08, 2018 / B3C newswire / — Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced two additions to its global commercial leadership team, appointing Robin Kenselaar as senior vice president and general manager, EMEA commercial operations, and Brad Mathis as vice president, U.S. commercial operations. These two key appointments serve to build Orchard’s initial commercial infrastructure across North America and EMEA prior to the Company’s first three potential product launches. Mr. Kenselaar and Mr. Mathis will report to Jason Meyenburg, chief commercial officer.
“We are thrilled to welcome Robin and Brad to the Orchard team, with their decades of experience and proven success leading international and domestic commercial operations for companies targeting rare diseases,” said Jason Meyenburg. “With three submissions for product approvals anticipated over the next three years and several additional therapies in development, the recent expansion of our commercial leadership team marks an important milestone as we prepare for the potential launches of these late-stage gene therapies, focusing especially on market access preparations and further development of patient diagnosis pathways.”
Robin Kenselaar joins Orchard after almost 15 years at Sanofi Genzyme, where he built and led commercial operations throughout Europe for therapies addressing unmet needs such as rare genetic diseases, oncology and immunology. During his tenure at Genzyme, Mr. Kenselaar served in various commercial leadership roles, most recently as head of Europe, and previously held positions as head of the EMEA region, vice president of commercial operations and business unit director, rare diseases. He has demonstrated consistent success working with key stakeholders to secure registration and expedited access to therapy and led the launches for a number of important therapies throughout Europe. Mr. Kenselaar holds a master’s of business administration from Nyenrode Business University (Netherlands).Back to News